[HTML][HTML] Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases
V Gelsi-Boyer, M Brecqueville, R Devillier… - Journal of hematology & …, 2012 - Springer
V Gelsi-Boyer, M Brecqueville, R Devillier, A Murati, MJ Mozziconacci, D Birnbaum
Journal of hematology & oncology, 2012•SpringerThe ASXL1 gene is one of the most frequently mutated genes in malignant myeloid
diseases. The ASXL1 protein belongs to protein complexes involved in the epigenetic
regulation of gene expression. ASXL1 mutations are found in myeloproliferative neoplasms
(MPN), myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and
acute myeloid leukemia (AML). They are generally associated with signs of aggressiveness
and poor clinical outcome. Because of this, a systematic determination of ASXL1 mutational …
diseases. The ASXL1 protein belongs to protein complexes involved in the epigenetic
regulation of gene expression. ASXL1 mutations are found in myeloproliferative neoplasms
(MPN), myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and
acute myeloid leukemia (AML). They are generally associated with signs of aggressiveness
and poor clinical outcome. Because of this, a systematic determination of ASXL1 mutational …
Abstract
The ASXL1 gene is one of the most frequently mutated genes in malignant myeloid diseases. The ASXL1 protein belongs to protein complexes involved in the epigenetic regulation of gene expression. ASXL1 mutations are found in myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML). They are generally associated with signs of aggressiveness and poor clinical outcome. Because of this, a systematic determination of ASXL1 mutational status in myeloid malignancies should help in prognosis assessment.
Springer